公开(公告)号：US20240316109A1

公开(公告)日：2024-09-26

申请号：US18277618

申请日：2022-02-18

Applicant: PUREC CO., LTD.

Inventor： Takeshi TAKETANI ,  Yasuaki ODA ,  Yumi IYOKU ,  Takashi SUYAMA

IPC: A61K35/28 ,  A61K35/51 ,  A61P19/08

CPC classification number: A61K35/28 ,  A61K35/51 ,  A61P19/08

Abstract: The present invention provides a pharmaceutical composition for increasing osteoblasts in a subject, which comprises high-purity mesenchymal stem cells, wherein the pharmaceutical composition is used in combination with hematopoietic stem cell transplantation to the subject.

公开(公告)号：US12024544B2

公开(公告)日：2024-07-02

申请号：US17991219

申请日：2022-11-21

Applicant: Rosalind Franklin University of Medicine & Science

Inventor： Bruce L. Riser

IPC: C07K14/47 ,  A61K9/00 ,  A61K35/12 ,  A61K35/28 ,  A61K35/51 ,  A61K38/04 ,  A61K38/10 ,  A61K38/17 ,  C07K14/475

CPC classification number: C07K14/47 ,  A61K9/0014 ,  A61K35/12 ,  A61K35/28 ,  A61K35/51 ,  A61K38/04 ,  A61K38/10 ,  A61K38/1709 ,  C07K14/4743 ,  C07K14/475 ,  A61K35/28 ,  A61K2300/00 ,  A61K35/51 ,  A61K2300/00

Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

公开(公告)号：US20240165166A1

公开(公告)日：2024-05-23

申请号：US18043064

申请日：2021-09-30

Applicant: OSIRIS THERAPEUTICS, INC.

Inventor： Chaoyang LI ,  Vimal JACOB ,  Min Sung PARK ,  Sandeep DHALL ,  Malathi SATHYAMOORTHY

IPC: A61K35/50 ,  A61K35/51 ,  A61P9/10 ,  A61P17/02

CPC classification number: A61K35/50 ,  A61K35/51 ,  A61P9/10 ,  A61P17/02

Abstract: Disclosed are methods and compositions useful for regenerative medicine for the therapeutic regeneration and repair of cells, tissues, or organs. The present disclosure relates to methods of priming viable placental tissue, primed viable placental tissue, and products thereof. Various priming techniques are disclosed including exposure viable placental tissue to hypoxia, UV light, bioactive materials, or combinations thereof.

公开(公告)号：US20240157029A1

公开(公告)日：2024-05-16

申请号：US18419226

申请日：2024-01-22

Applicant: James Glenn Norman

Inventor： James Glenn Norman

IPC: A61L27/38 ,  A61K35/28 ,  A61K35/50 ,  A61K35/51

CPC classification number: A61L27/3839 ,  A61K35/28 ,  A61K35/50 ,  A61K35/51 ,  A61L27/3834 ,  A61K35/14

Abstract: A method includes covering or contacting a portion of a parathyroid of a subject with a shield including biologic tissue. The covering or contacting occurs during a neck or reconstructive surgery of the subject.

公开(公告)号：US11883435B2

公开(公告)日：2024-01-30

申请号：US16487609

申请日：2018-06-15

Applicant: Indiana University Research and Technology Corporation

Inventor： Hal Edward Broxmeyer ,  Maegan Lynn Capitano ,  Scott Harrison Cooper ,  Qingchun Cai

IPC: A61K35/28 ,  A61K35/51 ,  A61K35/14 ,  A61K31/198 ,  A61K31/661 ,  A61K35/44

CPC classification number: A61K35/28 ,  A61K31/198 ,  A61K31/661 ,  A61K35/14 ,  A61K35/44 ,  A61K35/51

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of a condition/disease associated with insufficient quantity and/or quality of hematopoietic stem cells (HSCs) and differentiated blood cells thereof. Embodiments include compositions and methods for treating the condition/disease, comprising the step of providing to a subject at least one therapeutically effective dose of a composition disclosed herein. Other embodiments include methods for generating and/or collecting hematopoietic stem cells from a subject.

公开(公告)号：US11878036B2

公开(公告)日：2024-01-23

申请号：US18321644

申请日：2023-05-22

Applicant: Neuvian LLC

Inventor： Spencer Bouhadir ,  Jacob Miguel

IPC: A61K35/32 ,  A61K35/12 ,  A61K35/35 ,  A61K35/407 ,  A61K35/42 ,  A61K35/50 ,  A61K35/51 ,  A61K9/00 ,  A61K9/16 ,  A61K9/48 ,  A61K31/4172 ,  A61K45/06 ,  A61K47/02 ,  A61P15/00 ,  A61P15/02

CPC classification number: A61K35/32 ,  A61K9/0034 ,  A61K9/1611 ,  A61K9/1658 ,  A61K9/1664 ,  A61K9/485 ,  A61K9/4833 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875 ,  A61K31/4172 ,  A61K35/12 ,  A61K35/35 ,  A61K35/407 ,  A61K35/42 ,  A61K35/50 ,  A61K35/51 ,  A61K45/06 ,  A61K47/02 ,  A61P15/00 ,  A61P15/02

Abstract: The instant disclosure is directed to a vaginal care composition that restores pH balance, and thereby reduces vaginal dryness, irritation, dyspareunia, post-coital bleeding, infections, vaginal and pelvic pain and increases vaginal lubrication. In some embodiments, the vaginal care composition comprises stem cell-derived exosomes (e.g., mesenchymal stem cell (MSC)-derived exosomes), an antioxidant and a pH buffer. Another aspect of the disclosure is directed to methods for improving vaginal health by administering the vaginal care composition of the instant disclosure.

公开(公告)号：US20240000854A1

公开(公告)日：2024-01-04

申请号：US18265110

申请日：2021-12-06

Applicant: PRIMORIS THERAPEUTICS Co., Ltd.

Inventor： Jae-yong LEE ,  Hee-jin AHN ,  Yea-in LEE ,  Dong-yeol LEE ,  Kyu-heum NA

IPC: A61K35/51 ,  C12N5/0775 ,  A61K8/98 ,  A61P29/00 ,  A61K9/00 ,  A61Q19/08 ,  A61K9/06

CPC classification number: A61K35/51 ,  C12N5/0665 ,  A61K8/983 ,  A61P29/00 ,  A61K9/0014 ,  A61Q19/08 ,  A61K9/06

Abstract: A method for producing high-concentration stem cell exosomes with enhanced anti-inflammatory function using Lipopolysaccharide (LPS) and/or Lipoteichoic Acid (LTA), as well as anti-inflammatory and/or regenerative compositions that can be produced by the aforementioned method are disclosed. The production method for the anti-inflammatory composition includes a first step of treating stem cells during cultivation with one or more selected from a group consisting of Lipopolysaccharide (LPS) and Lipoteichoic Acid (LTA), and optionally, a second step of separating stem cells, their culture medium, and/or their exosomes obtained as a result of the first step.

公开(公告)号：US20240000704A1

公开(公告)日：2024-01-04

申请号：US17914691

申请日：2021-04-02

Applicant: TissueTech, Inc.

Inventor： Scheffer TSENG ,  Sean TIGHE ,  Ek Kia TAN ,  Jason Eric VEVODA

IPC: A61K9/00 ,  A61K35/51 ,  A61P27/02 ,  A61K35/50 ,  A61K45/06

CPC classification number: A61K9/0051 ,  A61K35/51 ,  A61P27/02 ,  A61K35/50 ,  A61K45/06

Abstract: Disclosed herein are methods of treating an ocular surface disease, disorder, or wound comprising applying an umbilical cord sheet and/or a controlled-release formulation to a tissue or surrounding tissue of an eye of a subject, such as the inferior fornix, superior fornix, and/or cornea. Further disclosed herein are kits for treatment of an ocular surface disease, disorder, or wound comprising the umbilical cord sheet and/or controlled-release formulation and a device for delivering and applying the umbilical cord sheet and/or controlled-release formulation to an eye of a subject.

公开(公告)号：US11813294B2

公开(公告)日：2023-11-14

申请号：US17170373

申请日：2021-02-08

Applicant: DUKE UNIVERSITY

Inventor： Joanne Kurtzberg ,  Geraldine Dawson ,  Jesse Troy ,  Jessica Sun

IPC: A61K35/14 ,  A61K35/51 ,  A61B5/16 ,  A61P43/00 ,  A61B5/055 ,  A61B5/00 ,  A61K9/00 ,  A61B5/369

CPC classification number: A61K35/51 ,  A61B5/055 ,  A61B5/163 ,  A61B5/369 ,  A61B5/4848 ,  A61K9/0019 ,  A61P43/00

Abstract: The present disclosure provides methods for the treatment of autism spectrum disorders. More particularly, the present disclosure relates to methods of using cord blood for the treatment of autism spectrum disorders.

公开(公告)号：US20230340410A1

公开(公告)日：2023-10-26

申请号：US18343187

申请日：2023-06-28

Applicant: Gamida Cell Ltd.

Inventor： Tony PELED ,  Einat Galamidi Cohen ,  David Synder

IPC: C12N5/078 ,  A61P7/00 ,  A61P31/00 ,  A61P35/02 ,  A01N1/02 ,  A61K35/51

CPC classification number: C12N5/0634 ,  A61P7/00 ,  A61P31/00 ,  A61P35/02 ,  A01N1/0284 ,  A61K35/51

Abstract: Methods of selecting umbilical cord blood units for ex-vivo expansion, separation of CD133+/CD34+ positive and uncultured CD133+/CD34+ negative fractions, methods for expanding the selected CD133+/CD34+ fraction, selection of expanded populations of CD133+/CD34+ cord blood cells for transplantation to subjects in need thereof and the therapeutic use of suitable selected, ex-vivo expanded CD133+/CD34+ and unselected CD133/CD34 negative cord blood fractions for transplantation in the clinical setting, for treatment of hematological malignancies are provided. The present invention also envisions kits comprising the expanded and unselected cord blood fractions.